logo-loader

Musk confirms talks with TSMC over Terafab chip plant

Last updated: 09:46 05 Oct 2026 EDT, First published: 08:46 05 Oct 2026 EDT

SpaceX Corp - Musk confirms talks with TSMC over Terafab chip plant

Taiwan Semiconductor Manufacturing Co (ADR) (NYSE:TSM), the world's largest contract chipmaker, is in talks with Elon Musk about building and running a factory that would serve only Tesla Inc (NASDAQ:TSLA), SpaceX Corp (NASDAQ:SPCX) and xAI for his Terafab chipmaking initiative.

Over the weekend, Musk confirmed on X that discussions were taking place but did not elaborate.

TSMC has not commented publicly, Musk did not elaborate, and neither company has confirmed any structure for a possible deal.

Culpan's likeliest structure has TSMC owning and operating the fab while SpaceX invests, commits to chip volumes, or does both, resembling the JASM and ESMC joint ventures.

An alternative would give SpaceX majority ownership, with TSMC operating the plant and supplying its process technology, a model that would be new for TSMC.

Nothing is official, and other structures beyond the two outlined could still emerge.

Wedbush Securities, the brokerage, considers that outcome an unlikely endpoint, and Culpium also links TSMC's rumored Texas fab complex to supporting Terafab.

Intel, the chipmaker, had been named to supply Terafab with 14A, its next-generation manufacturing process in the 1.4 nanometer class.

Wedbush expects a TSMC tie-up to rule out Terafab being built on Intel's 14A process, because TSMC would bring its own process technology to the plant.

Musk's choice of 14A had been viewed as a proof point for the quality of Intel's next-generation process, so Wedbush sees the development as a step back for Intel.

Terafab is intended to give Tesla, SpaceX and xAI an uninterrupted supply of custom chips for artificial intelligence, vehicles and spacecraft rather than compete as a foundry, or contract chipmaker, against TSMC.

Scancell CEO on FDA breakthrough, melanoma survival data and Phase 3 plans

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L’Huillier talked with Proactive's Stephen Gunnion about the company's latest clinical and regulatory progress, including FDA RMAT designation for its lead melanoma treatment, inzitagene plasmivec (iSCIB1+), updated survival data and...

3 hours, 11 minutes ago